DK4328309T3 - Lipidsammensætning - Google Patents

Lipidsammensætning

Info

Publication number
DK4328309T3
DK4328309T3 DK24150973.6T DK24150973T DK4328309T3 DK 4328309 T3 DK4328309 T3 DK 4328309T3 DK 24150973 T DK24150973 T DK 24150973T DK 4328309 T3 DK4328309 T3 DK 4328309T3
Authority
DK
Denmark
Prior art keywords
lipid composition
lipid
composition
Prior art date
Application number
DK24150973.6T
Other languages
Danish (da)
English (en)
Inventor
Takahiro Sekiguchi
Taisuke Endo
Shun KANEUMI
Masaki Noro
Shintaro Tanabe
Masahiko Yamamoto
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Application granted granted Critical
Publication of DK4328309T3 publication Critical patent/DK4328309T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/16Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dispersion Chemistry (AREA)
DK24150973.6T 2019-11-15 2020-11-13 Lipidsammensætning DK4328309T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019207118 2019-11-15
EP20886910.7A EP4059505B1 (en) 2019-11-15 2020-11-13 Lipid composition

Publications (1)

Publication Number Publication Date
DK4328309T3 true DK4328309T3 (da) 2025-08-18

Family

ID=75912395

Family Applications (1)

Application Number Title Priority Date Filing Date
DK24150973.6T DK4328309T3 (da) 2019-11-15 2020-11-13 Lipidsammensætning

Country Status (11)

Country Link
US (1) US20220273817A1 (https=)
EP (2) EP4059505B1 (https=)
JP (2) JP7389134B2 (https=)
KR (4) KR20250171478A (https=)
CN (2) CN117417265B (https=)
CA (1) CA3158293C (https=)
DK (1) DK4328309T3 (https=)
ES (1) ES3036322T3 (https=)
FI (1) FI4328309T3 (https=)
PL (1) PL4328309T3 (https=)
WO (1) WO2021095876A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102591743B1 (ko) 2018-06-08 2023-10-19 후지필름 가부시키가이샤 화합물 또는 그 염 및 지질 입자
WO2020246581A1 (ja) 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
CN117279888A (zh) * 2021-04-28 2023-12-22 富士胶片株式会社 化合物或其盐、脂质颗粒及药物组合物
CN114149337B (zh) * 2021-07-07 2022-04-29 天津键凯科技有限公司 一种用于核酸递送的新型可电离脂质及其lnp组合物
CN120420422A (zh) * 2022-01-30 2025-08-05 康希诺生物股份公司 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗
CN118891051A (zh) 2022-03-15 2024-11-01 富士胶片株式会社 脂质组合物
CN118984831A (zh) 2022-03-15 2024-11-19 富士胶片株式会社 化合物及脂质组合物
WO2023178425A1 (en) * 2022-03-23 2023-09-28 Nanovation Therapeutics Inc. High sterol-containing lipid nanoparticles
WO2024014430A1 (ja) 2022-07-11 2024-01-18 富士フイルム株式会社 アミノ脂質又はその塩の製造中間体としての化合物、及びそれを用いたアミノ脂質化合物の製造方法
AU2023316579A1 (en) 2022-07-29 2025-02-13 Fujifilm Corporation COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
JP2025537180A (ja) * 2022-11-03 2025-11-14 シャンハイ サーコード バイオメッド カンパニー,リミティド 脂質化合物、脂質ナノ粒子、及び医薬組成物
WO2024158042A1 (ja) * 2023-01-27 2024-08-02 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
AU2024234895A1 (en) 2023-03-13 2025-09-18 Fujifilm Corporation Compound or salt thereof, lipid composition, pharmaceutical composition, and delivery carrier
WO2025070702A1 (ja) * 2023-09-27 2025-04-03 富士フイルム株式会社 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物
WO2025143232A1 (ja) * 2023-12-28 2025-07-03 富士フイルム株式会社 免疫細胞への核酸送達剤、および免疫細胞に核酸を送達する方法
WO2025192731A1 (ja) * 2024-03-15 2025-09-18 富士フイルム株式会社 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア
WO2026004829A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
WO2026004828A1 (ja) * 2024-06-24 2026-01-02 富士フイルム株式会社 脂質ナノ粒子の製造方法
CN120535478A (zh) * 2025-01-23 2025-08-26 上海环码生物医药有限公司 脂质化合物、脂质纳米颗粒和药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
JP5288254B2 (ja) 2008-10-17 2013-09-11 株式会社ニコン レンズ系
CN111808084A (zh) 2008-11-10 2020-10-23 阿布特斯生物制药公司 用于递送治疗剂的新型脂质和组合物
KR101766408B1 (ko) 2009-06-10 2017-08-10 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
JP2013245107A (ja) 2012-05-29 2013-12-09 Kuma Lift Gijutsu Kenkyusho:Kk 椅子式階段昇降装置
TW201534578A (zh) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd 新穎脂質
US10426737B2 (en) * 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
HUE060907T2 (hu) * 2014-06-25 2023-04-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére
JP6637988B2 (ja) 2014-11-18 2020-01-29 アークトゥルス セラピューティクス, インコーポレイテッド Rna送達のためのイオン化可能カチオン性脂質
CA3040337A1 (en) * 2016-10-26 2018-05-03 Curevac Ag Lipid nanoparticle mrna vaccines
AU2017356699B2 (en) * 2016-11-08 2021-11-11 Ramot At Tel-Aviv University Ltd. Cationic lipids for nucleic acid delivery and preparation thereof
KR102591743B1 (ko) * 2018-06-08 2023-10-19 후지필름 가부시키가이샤 화합물 또는 그 염 및 지질 입자
WO2020246581A1 (ja) * 2019-06-07 2020-12-10 富士フイルム株式会社 脂質組成物
EP4059505B1 (en) * 2019-11-15 2024-02-21 FUJIFILM Corporation Lipid composition
JP7518909B2 (ja) * 2020-09-14 2024-07-18 富士フイルム株式会社 脂質組成物

Also Published As

Publication number Publication date
CN114728016A (zh) 2022-07-08
ES3036322T3 (en) 2025-09-17
FI4328309T3 (fi) 2025-09-09
JP7389134B2 (ja) 2023-11-29
US20220273817A1 (en) 2022-09-01
KR20220082885A (ko) 2022-06-17
JPWO2021095876A1 (https=) 2021-05-20
PL4328309T3 (pl) 2025-11-17
EP4059505A4 (en) 2023-01-11
WO2021095876A1 (ja) 2021-05-20
CN117417265A (zh) 2024-01-19
KR20250171478A (ko) 2025-12-08
CA3158293C (en) 2024-06-25
EP4328309A2 (en) 2024-02-28
EP4059505B1 (en) 2024-02-21
EP4328309B1 (en) 2025-07-02
KR20250057122A (ko) 2025-04-28
EP4059505A1 (en) 2022-09-21
KR20240090627A (ko) 2024-06-21
CN114728016B (zh) 2024-10-29
CN117417265B (zh) 2026-02-10
EP4328309A3 (en) 2024-09-25
JP7566078B2 (ja) 2024-10-11
CA3158293A1 (en) 2021-05-20
JP2023116626A (ja) 2023-08-22

Similar Documents

Publication Publication Date Title
DK4328309T3 (da) Lipidsammensætning
EP3981435A4 (en) FAT COMPOSITION
DK3924443T3 (da) Compositions
EP3853332C0 (en) COMPOSITION
EP3882323A4 (en) COMPOSITION
EP3930851A4 (en) COMBINATION THERAPIES
EP3919491C0 (en) AKT INHIBITOR
SI3927315T1 (sl) Okusne formulacije
EP3871694A4 (en) COMPOSITION
DK3840596T3 (da) Sammensætning
EP3742771C0 (en) M2M SM-SR TO SM-DP NOTIFICATION
EP3981256A4 (en) COMPOSITION
EP3941942A4 (en) COMPOSITION
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP4049824C0 (en) MOLD
EP3954721A4 (en) Composition
EP3999039A4 (en) PRETOMANID COMPOSITIONS
EP3914303C0 (en) VIRUCIDAL COMPOSITION
DK3908321T3 (da) Farmaceutisk sammensætning
EP3741814C0 (en) COMPOSITION
PT3765379T (pt) Composições
DK3911298T3 (da) Formuleringer
DK3738452T3 (da) Fordamper
EP3805997A4 (en) LIPIDNANOTABLET
EP3829532A4 (en) KERATIN COMPOSITIONS